Altered p16 and Bcl-2 expression reflects pathologic development in hydatidiform moles and choriocarcinoma.
Abnormal trophoblast differentiation is the main cause of gestational trophoblast diseases in the case of hydatidiform moles and choriocarcinomas. Here we investigated the expression patterns of two gene products, p16 and Bcl-2, implicated in cell cycle regulation and apoptosis, respectively, using immunohistochemistry during normal placenta differentiation, hydatidiform moles (partial, complete and invasive) and post-molar choriocarcinomas. The p16 protein shows a gradual expression in cytotrophoblast of normal villous, from a p16 weak proliferative phenotype to a p16 strong invasive phenotype reaching a maximum around 17 weeks of gestation. The expression pattern in cytotrophoblast was similar in moles in contrast to the villous mesenchyme of invasive moles where p16 was strongly expressed. Bcl-2 expression was syncytiotrophoblast specific in normal placenta and moles and increased gradually during normal differentiation. The results explain the persistence of normal and molar villous fragments during their development and their dramatic invasion in the uterine arteries in case of invasive moles. In choriocarcinomas the weak Bcl-2 expression is associated with weak p16 expression indicating a great apoptotic and proliferative potentials. The results suggest that strong p16 expression in the villous mesenchyme may be responsible in part of the morbidity of the moles, and the key of cancer progression in the choriocarcinomas would be a fast cell-cycle turnover.
INSERM U782 Endocrinologie et génétique de la reproduction et du développement, 32 rue des Carnets, 92140, Clamart, France. jean-jacques.candelier@u-psud.fr
Jean-Jacques
JJ
Candelier
Lucien
L
Frappart
Tarik
T
Yadaden
Henriette
H
Poaty
Jean-Yves
JY
Picard
Sophie
S
Prévot
Philippe
P
Coullin
D002453:Cell Cycle / Q000235:genetics; D002454:Cell Differentiation / Q000235:genetics; D002822:Choriocarcinoma / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000096:biosynthesis* / Q000235:genetics; D018450:Disease Progression; D005260:Female; D031901:Gestational Trophoblastic Disease / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D006801:Humans; D006828:Hydatidiform Mole / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D002820:Hydatidiform Mole, Invasive / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D010920:Placenta / Q000473:pathology; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000096:biosynthesis* / Q000235:genetics; D014594:Uterine Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology*
D019941:Cyclin-Dependent Kinase Inhibitor p16; D019253:Proto-Oncogene Proteins c-bcl-2